Ask to take part

Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.

Contact Information:

Study Location:

University College London Hospitals

Skip to Main Content

Focal Prostate Radiofrequency Ablation

Not Recruiting

Open to: Male

Age: 40 Years - N/A

Medical Conditions

Prostate Cancer

To assess the early histological outcomes of tissue ablation, adverse events and genitourinary side-effect profile of focal radiofrequency ablation using a coiled bipolar device to treat localized prostate cancer in men with clinically significant prostate cancer.

The study aims to assess the ability of focal therapy using coiled bipolar radiofrequency device to ablate a pre-defined target tissue zone as well as assess side-effects. The medical device has a coiled configuration and creates thus a "Faraday cage" effect, preventing surrounding tissue damage and the bipolar configuration produces complete tissue thermo coagulation within the limits the coil. Thereof it is proposed to conduct a prospective development study, offering focal therapy coiled bipolar radiofrequency ablation to men with histologically proven localized prostate cancer which is clinically significant. Localization and characterization of the disease will be established using multi-parametric magnetic resonance imaging (mp-MRI) and transperineal prostate biopsies. Magnetic resonance (MR)-visible, clinically significant disease will be targeted and focally treated with a margin of normal tissue as big as anatomically possible to obtain an adequate margin of normal tissue around the lesion for effective ablation. Secondary lesions meeting criteria for clinical insignificance will be left untreated and undergo surveillance. Pre-operative and all post operative imaging will be performed using a scanner and a pelvic phased array receiver, with a pelvic coil. A full protocol of T1 and T2 weighted turbo-spin echo images and a dynamic post gadolinium volume acquisition will be used for both pre-operative diagnostic and planning scans and post-operative assessment by use of the medical device. The initial transperineal biopsy will already have been performed, prior to invitation to participate in the study, and demonstrating eligibility for inclusion. The process will involve targeted or mapping biopsies which are concordant with the lesion seen on MRI. In both cases, transperineal biopsies will be taken from the prostate using a brachytherapy grid placed over the perineal skin whilst the man is in the lithotomy position. They will be given as much time as they need to consider whether or not patients wish to participate. The ones who wish to participate after reading the patient information sheet will undergo a screening visit (first visit) to ascertain whether or not they are eligible for the trial. If so, they will proceed to focal radiofrequency ablation using a coiled bipolar device(second visit), and will be seen at further follow-up visits.

$trialDetailsjson.studyDesign.replaceAll("\n\n", "

").replaceAll("\n", "").replaceAll("\u00A0", " ")

Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.  

The recruitment start and end dates are as follows:

Mar 2015

Apr 2018


Intervention Type : Procedure
Intervention Name : Coiled Bipolar Radiofrequency Ablation
Intervention Description : Radiofrequency ablation by use of bipolar electrodes

Intervention Arm Group : ProRAFT

You can take part if:

Inclusion Criteria: - Histologically proven prostate cancer - A visible lesion on multiparametric Magnetic Resonance Imaging (mpMRI), that is accessible to a treatment based on radiofrequency bipolar electrodes - Transperineal prostate biopsies (template mapping and/or targeted) correlating with clinically significant lesion in the area of the Magnetic Resonance (MR)-visible lesion - Absence of clinically significant histological disease outside of the planned treatment zone - Radiological stage T1-T3aN0M0 disease, as determined by local guidelines - Serum prostate-specific antigen (serum PSA)

You may not be able to take part if:

This is in the inclusion criteria above

Below are the locations for where you can take part in the trial. Please note that not all sites may be open.

  • University College London Hospitals
    NW1 2PS

The study is sponsored by Trod Medical N.V. .

We'd like your feedback

Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.

Is this study information helpful?

What will you do next?

Read full details

for Trial ID: NCT02294903

Last updated

This page is to help you find out about a research study and if you may be able to take part

The information is provided by researchers and we rely on them to keep it up-to-date. You can see more information by clicking on the 'Read full details' link above.

To take part, please print or share the study information with your GP/healthcare provider or contact the research team directly.